CN1127502C - 帕罗西汀甲磺酸盐 - Google Patents

帕罗西汀甲磺酸盐 Download PDF

Info

Publication number
CN1127502C
CN1127502C CN99810281A CN99810281A CN1127502C CN 1127502 C CN1127502 C CN 1127502C CN 99810281 A CN99810281 A CN 99810281A CN 99810281 A CN99810281 A CN 99810281A CN 1127502 C CN1127502 C CN 1127502C
Authority
CN
China
Prior art keywords
mes
pot
solution
crystallization
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN99810281A
Other languages
English (en)
Chinese (zh)
Other versions
CN1315949A (zh
Inventor
V·W·杰斯维茨
M·W·J·乌尔屈哈特
A·S·克赖格
D·A·琼斯
D·奥克菲
N·瓦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1127502(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1315949A publication Critical patent/CN1315949A/zh
Application granted granted Critical
Publication of CN1127502C publication Critical patent/CN1127502C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN99810281A 1998-07-02 1999-04-23 帕罗西汀甲磺酸盐 Expired - Fee Related CN1127502C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GB9814316.7 1998-07-02
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GB9821732.6 1998-10-06
GB9902935.7 1999-02-10
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound

Publications (2)

Publication Number Publication Date
CN1315949A CN1315949A (zh) 2001-10-03
CN1127502C true CN1127502C (zh) 2003-11-12

Family

ID=27269380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99810281A Expired - Fee Related CN1127502C (zh) 1998-07-02 1999-04-23 帕罗西汀甲磺酸盐

Country Status (34)

Country Link
US (4) US6063927A (enExample)
EP (5) EP0970955B1 (enExample)
JP (1) JP2002519422A (enExample)
KR (1) KR20010053336A (enExample)
CN (1) CN1127502C (enExample)
AR (2) AR011759A1 (enExample)
AT (4) ATE251155T1 (enExample)
AU (4) AU713877B3 (enExample)
BE (3) BE1012403A5 (enExample)
BR (1) BR9911682A (enExample)
CA (1) CA2269999A1 (enExample)
CH (1) CH689805A8 (enExample)
DE (5) DE69911774T2 (enExample)
DK (7) DK199900176U3 (enExample)
ES (4) ES2209428T3 (enExample)
FI (2) FI4209U1 (enExample)
FR (2) FR2780728B1 (enExample)
GB (5) GB2339428A (enExample)
GR (3) GR990100140A (enExample)
HU (1) HUP0102334A3 (enExample)
IE (5) IE20000633A1 (enExample)
IL (1) IL140628A (enExample)
IT (1) IT1312540B1 (enExample)
LU (1) LU90388B1 (enExample)
NL (4) NL1011875C2 (enExample)
NO (1) NO319030B1 (enExample)
NZ (1) NZ509180A (enExample)
PL (1) PL345214A1 (enExample)
PT (4) PT1089996E (enExample)
SE (1) SE9901462A0 (enExample)
SI (3) SI1089996T1 (enExample)
SK (1) SK20262000A3 (enExample)
TR (1) TR200100054T2 (enExample)
WO (1) WO2000001694A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
WO1998037938A1 (en) * 1997-02-27 1998-09-03 Ajinomoto Co., Inc. Crystallization apparatus and crystallization method
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
HUP0303827A2 (hu) * 2000-08-28 2004-04-28 Synthon B.V. Paroxetinkészítmények és eljárások ezek előállítására
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1874908B1 (en) 2005-04-07 2014-06-11 Xy, Llc Method for reducing microorganisms in a flow path using diacetone alcohol
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
CA2679484A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2,5-dione
US20100249166A1 (en) 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (enExample) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
JPS63141967A (ja) * 1986-11-21 1988-06-14 エイ・エッチ・ロビンス・カンパニー・インコーポレーテッド 抗アレルギー薬として有用な１−アリールオキシー４−［（４−アリール）−１−ピペラジニル］−２−ブタノール
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
WO1992009281A2 (en) * 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
NZ307479A (en) * 1995-05-17 1999-08-30 Novo Nordisk As A process for preparing 4-(4-halo substituted phenyl)-3-(3,4-methylenedioxy phenoxy methyl)piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Process for drying paroxetine hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
KR100543614B1 (ko) * 1997-06-10 2006-01-20 신톤 비.브이. 4-페닐피페리딘 화합물
KR20010040711A (ko) * 1998-02-06 2001-05-15 피터 기딩스 파록세틴의 염
BR9908825A (pt) * 1998-03-16 2000-11-21 Smithkline Beecham Plc Forma cristalina de paroxetina
JP2002511466A (ja) * 1998-04-09 2002-04-16 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー マレイン酸パロキセチン
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Also Published As

Publication number Publication date
NO991944D0 (no) 1999-04-23
HUP0102334A2 (hu) 2002-05-29
FI990922A0 (fi) 1999-04-23
EP1020463A1 (en) 2000-07-19
DE69900007D1 (de) 2000-09-07
IL140628A (en) 2004-06-20
SK20262000A3 (sk) 2001-07-10
ITMI990866A1 (it) 2000-10-23
DK1089996T3 (da) 2004-02-09
EP1089996A1 (en) 2001-04-11
BE1011664A6 (fr) 1999-11-09
DK200000390U1 (da) 2000-12-27
DK199900234U4 (da) 2000-12-22
ES2158778B1 (es) 2002-03-16
GB2352395B (en) 2004-02-11
ES2158778A1 (es) 2001-09-01
DE69900007T2 (de) 2001-06-07
FI4209U1 (fi) 1999-11-10
NL1012271C2 (nl) 1999-09-23
ATE195121T1 (de) 2000-08-15
DE60000003D1 (de) 2001-08-09
DE29907248U1 (de) 1999-09-09
SI1020464T1 (en) 2001-12-31
AR018197A1 (es) 2001-10-31
EP0970955A1 (en) 2000-01-12
SI1089996T1 (en) 2004-04-30
CA2269999A1 (en) 2000-01-02
EP1020464A1 (en) 2000-07-19
CH689805A8 (fr) 2000-02-29
LU90388B1 (fr) 2001-01-29
SE9901462D0 (sv) 1999-04-23
GB2336364B (en) 2000-05-10
NL1011875A1 (nl) 2000-01-07
DE60000003T2 (de) 2002-03-21
GB0026487D0 (en) 2000-12-13
DK199900234U1 (da) 2000-12-22
TR200100054T2 (tr) 2001-06-21
AU3619199A (en) 2000-01-24
ES2209428T3 (es) 2004-06-16
FR2802098A1 (fr) 2001-06-15
JP2002519422A (ja) 2002-07-02
FIU990190U0 (fi) 1999-04-23
GB2352395A (en) 2001-01-31
ES2149044T3 (es) 2000-10-16
AU732211C (en) 2004-05-06
EP0970955B1 (en) 2000-08-02
EP1020464B1 (en) 2001-07-04
SE9901462L (enExample)
GR990100140A (el) 2000-03-31
GR3034328T3 (en) 2000-12-29
PT102291A (pt) 2000-05-31
AU2392899A (en) 2000-01-20
GR1003350B (el) 2000-03-29
DE19918588A1 (de) 2000-01-27
GB2367003A (en) 2002-03-27
NL1011875C2 (nl) 2000-03-24
AT3185U2 (de) 1999-11-25
GB2377637A (en) 2003-01-22
GB2336364A (en) 1999-10-20
IE20000633A1 (en) 2001-10-17
US20020035130A1 (en) 2002-03-21
CN1315949A (zh) 2001-10-03
AU713877B3 (en) 1999-12-09
CH689805A5 (fr) 1999-11-30
AR011759A1 (es) 2000-09-13
ATE202777T1 (de) 2001-07-15
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
WO2000001694A1 (en) 2000-01-13
ES2157881T3 (es) 2001-09-01
BE1012403A5 (fr) 2000-10-03
SE9901462A0 (sv) 2000-01-03
PT970955E (pt) 2000-11-30
HK1037877A1 (en) 2002-02-22
BE1012420A6 (fr) 2000-10-03
IES20000893A2 (en) 2001-05-30
FI990922L (fi) 2000-01-03
FR2780728B1 (fr) 2001-02-16
PL345214A1 (en) 2001-12-03
AU732211B2 (en) 2001-04-12
KR20010053336A (ko) 2001-06-25
NZ509180A (en) 2001-06-29
NL1011874C1 (nl) 1999-07-12
ATE251155T1 (de) 2003-10-15
DK199900176U3 (da) 1999-08-13
DK0970955T3 (da) 2000-10-09
GB9920332D0 (en) 1999-11-03
IES20000894A2 (en) 2001-05-30
GB9909505D0 (en) 1999-06-23
NL1012272C1 (nl) 1999-07-12
AU713131B3 (en) 1999-11-25
BR9911682A (pt) 2001-12-26
GB2339428A (en) 2000-01-26
IT1312540B1 (it) 2002-04-22
AT3185U3 (de) 2000-01-25
FI112077B (fi) 2003-10-31
IES990343A2 (en) 2000-01-02
EP1288214A1 (en) 2003-03-05
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
DK199900554A (da) 2000-01-03
US6063927A (en) 2000-05-16
FR2780728A1 (fr) 2000-01-07
PT102291B (pt) 2002-07-31
GR3036208T3 (en) 2001-10-31
EP1089996B1 (en) 2003-10-01
NO319030B1 (no) 2005-06-06
DK1020464T3 (da) 2001-09-24
SI0970955T1 (en) 2001-02-28
US20010023253A1 (en) 2001-09-20
IES81166B2 (en) 2000-05-31
PT1020464E (pt) 2001-10-30
HUP0102334A3 (en) 2003-12-29
US20020193406A1 (en) 2002-12-19
IE990344A1 (en) 2000-05-03
NO991944L (no) 2000-01-03
DE69911774T2 (de) 2004-08-05
DE69911774D1 (de) 2003-11-06
IL140628A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
CN1127502C (zh) 帕罗西汀甲磺酸盐
CN1216055C (zh) 新的帕罗西汀盐酸盐无水合物及其制备方法和用途
CN1036458C (zh) 稠合杂环化合物的制备方法
CN1463191A (zh) 低吸湿性阿立哌唑药物及其制备方法
CN1656077A (zh) 制备手性二醇砜和二羟基酸HMGCoA还原酶抑制剂的方法
CN1668623A (zh) 一种拟多晶型hiv蛋白酶抑制剂
CN1589256A (zh) 盐酸舍曲林的新多晶型物和含有它们的组合物,制备盐酸舍曲林多晶型物和无定形物的新方法
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1024626C (zh) 含有四氢苯并[c，d]吲哚5-羟色胺兴奋剂的组合物的制备方法
CN1226825A (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1058207A (zh) 新的哌啶化合物及其制备方法
CN1105990A (zh) 苯基链烷醇胺衍生物
CN85107496A (zh) 制备四氢化萘衍生物的方法
CN1067985C (zh) 吲哚衍生物及含它们的药物
CN1922179A (zh) 盐酸伐昔洛韦的结晶形式
CN1123546A (zh) 4-芳基异吲哚止痛药
CN1098415A (zh) 亚水杨基氨基过渡金属配合物及其制法
CN1037510C (zh) 制备吲哚衍生物的方法
CN1222534C (zh) VI型5,6－二氯－2－(异丙基氨基)－1－(β－L－呋喃核糖基)－1H－苯并咪唑
CN1665504A (zh) 新晶型的加替沙星
CN1345317A (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物
CN1015622B (zh) 氢化肉桂酸衍生物和其制法
CN88102858A (zh) 可用作抗高血压剂的肼衍生物的制备方法
CN1662523A (zh) 新颖的方法
CN1023479C (zh) 乙二胺的单酰胺衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20031112